Treatment of Dientamoeba fragilis in Patients with Irritable Bowel Syndrome

Choung, 2011, Epidemiology of IBS, 40, 1

Spiegel, 2009, The burden of IBS: looking at metrics, 11, 265

Longstreth, 2006, Functional bowel disorders, 130, 1480

El-Serag, 2002, Health-related quality of life among persons with irritable bowel syndrome: a systematic review, 16, 1171

Agarwal, 2011, The effect of irritable bowel syndrome on health-related quality of life and health care expenditures, 40, 11

Quigley, 2007, Systematic review on the management of irritable bowel syndrome in the European Union, 19, S11

Quigley, 2006, Irritable bowel syndrome: the burden and unmet needs in Europe, 38, 717

Thabane, 2007, Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome, 26, 535

Ghoshal, 2011, Post-infectious irritable bowel syndrome: the past, the present and the future, 26, 94

Jeffery, 2011, An irritable bowel syndrome subtype defined by species-specific alterations in fecal microbiota, 61, 997

Salonen, 2010, Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives, 156, 3205

Rajilic-Stojanovic, 2011, Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome, 141, 1792

Tana, 2010, Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome, 22, 512

Brenner, 2009, The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review, 104, 1033

Majewski, 2007, Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial, 52, 139

Pimentel, 2003, Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study, 98, 412

Pimentel, 2006, The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial, 145, 557

Pimentel, 2006, Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study, 51, 1297

Pimentel, 2011, Rifaximin therapy for patients with irritable bowel syndrome without constipation, 364, 22

Esposito, 2007, Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics, 13, 6016

Menees, 2012, The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis, 107, 28

Sharara, 2006, A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence, 101, 326

Barratt, 2011, A review of Dientamoeba fragilis carriage in humans: several reasons why this organism should be considered in the diagnosis of gastrointestinal illness, 2, 3

Stark, 2010, A review of the clinical presentation of dientamoebiasis, 82, 614

Lagace-Wiens, 2006, Dientamoeba fragilis: an emerging role in intestinal disease, 175, 468

Johnson, 2004, Emerging from obscurity: biological, clinical, and diagnostic aspects of Dientamoeba fragilis, 17, 553

Stensvold, 2009, Blastocystis: unravelling potential risk factors and clinical significance of a common but neglected parasite, 137, 1655

de Wit, 2001, Etiology of gastroenteritis in sentinel general practices in the Netherlands, 33, 280

Stark, 2007, Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis, 37, 11

Stark, 2005, Prospective study of the prevalence, genotyping, and clinical relevance of Dientamoeba fragilis infections in an Australian population, 43, 2718

Girginkardesler, 2003, Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole, 9, 110

Colea, 1980, Studies on Dientamoeba fragilis in Romania. II. Incidence of Dientamoeba fragilis in healthy persons, 39, 49

Borody, 2002, Eradication of Dientamoeba fragilis can resolve IBS-like symptoms, 17, A103

Stark, 2006, Dientamoebiasis: clinical importance and recent advances, 22, 92

Yakoob, 2010, Blastocystis hominis and Dientamoeba fragilis in patients fulfilling irritable bowel syndrome criteria, 107, 679

Jimenez-Gonzalez, 2012, Blastocystis infection is associated with irritable bowel syndrome in a Mexican patient population, 110, 1269

Engsbro, 2011, Diagnostic strategies in patients suspected of irritable bowel syndrome, 60, A58

Stensvold, 2007, Detecting Blastocystis using parasitologic and DNA-based methods: a comparative study, 59, 303

Stensvold, 2011, The prevalence and clinical significance of intestinal parasites in HIV-infected patients in Denmark, 43, 129

Camilleri, 2007, Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints, 5, 534

Nagata, 2012, In vitro susceptibility testing of Dientamoeba fragilis, 56, 487

Verweij, 2007, Real-time PCR for the detection of Dientamoeba fragilis in fecal samples, 21, 400

Yang, 1977, Dientamoeba fragilis: a review with notes on its epidemiology, pathogenicity, mode of transmission, and diagnosis, 26, 16

Cuffari, 1998, Dientamoeba fragilis masquerading as allergic colitis, 26, 16

Kurt, 2008, A comparison of metronidazole and single-dose ornidazole for the treatment of dientamoebiasis, 14, 601

Oxner, 1987, Dientamoeba fragilis: a bowel pathogen?, 100, 64

Preiss, 1991, On the clinical importance of Dientamoeba fragilis infections in childhood, 35, 27

Camilleri, 2007, Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints, 5, 534

Spiegel, 2009, Psychometric evaluation of patient-reported outcomes in irritable bowel syndrome randomized controlled trials: a Rome Foundation report, 137, 1944

Mangel, 2008, Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome, 28, 239

Chang, 2005, A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS, 100, 115

Drossman, 2008, Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome, 103, 2562

Bosman, 2004, Dientamoeba fragilis: possibly an important cause of persistent abdominal pain in children, 148, 575

Butler, 1996, Dientamoeba fragilis. An unusual intestinal pathogen, 41, 1811

Dardick, 1983, Tetracycline treatment of Dientamoeba fragilis, 47, 69

Millet, 1983, Dientamoeba fragilis, a protozoan parasite in adult members of a semicommunal group, 28, 335

Norberg, 2003, Dientamoeba fragilis–a protozoal infection which may cause severe bowel distress, 9, 65

Spencer, 1979, Dientamoeba fragilis. An intestinal pathogen in children?, 133, 390

Spencer, 1982, Dientamoeba fragilis: a gastrointestinal protozoan infection in adults, 77, 565

Vandenberg, 2007, Treatment of Dientamoeba fragilis infection with paromomycin, 26, 88